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Urinary metabolites of the (3 subunit of human chorionic
gonadotropin (hCG(3), particularly the fragment known as
(3-core, are potential tumor markers for gynecological can-
cers (1-6). We have found that an increased concentration
(tg’L) of (3-core in early-morning urine samples is rela-
tively common in gynecological cancers, but the sensitivity
(36%) and specificity (90%) of such measurements are low
(7). Most clinical studies have reported /3-core concentra-
tions in early-morning or random urine specimens without
correction for urine volume or concentration (1-7). For
many urinary solutes, however, including proteins, ex-
pressing the concentration as a ratio to the urinary creat-
inine concentration is less variable and may better reflect
the true urine output than does concentration per unit
volume (8-11).
In the present study, we examined the variation of uri-
nary (3-core excretion over a 24-h period, to determine
whether expressing (3-core results as a ratio to creatinine or
to total volume of urine gave results that were less variable
than concentrations per unit volume for any given early-
morning or random specimen.
Urine samples were obtained preoperatively from 35
women, ages 28-66 years. All were hospitalized for surgical
treatment of a benign (n = 8) or malignant (n = 27) gyne-
cological condition. The patients had serum creatinine con-
centrations within the normal reference range, were in
stable condition, and were selected from an inpatient pop-
ulation on the basis of their willingness to cooperate with
the study. The procedures followed were in accordance with
the ethical standards of our institution’s responsible com-
mittee. The women collected a portion from each urine
specimen passed during 24 h; 20 of these women recorded
both the volume and the time of each micturition. Sodium
aside (1 g/L) was added to the unprocessed urine, which was
stored at -20#{176}Cuntil analysis.
Results on 16 women were excluded: 11 because of failure
to conform to the collection protocol and 5 because there was
no measurable (3core in an early-morning urine specimen.
For the 24-h analysis, a complete set of samples was obtained
in 19 women (136 specimens, an average of 7 per subject).
We measured /3-core by RIA (detection limit 0.1 tg’L) as
described previously (12). In this assay, (3-core shows partial
cross-reactivity with intact hCG (6.9%) and free hCG(3 (18%)
and negligible cross-reactivity for luteinizing, thyroid-stim-
ulating, and follicle-stimulating hormones (<0.7%). Creati-
nine was measured by a kinetic Jaff#{233}method with a Hitachi
717 analyzer. The specimens from each woman were thawed
and analyzed in a single assay. One analyst performed all
the assays, and the same batches of reagents were used
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throughout. The between-assay variability (CV) ranged
from 2.3% to 13.4% for /3-core (0.1 to 5 j.tg/L) and from 2.5%
to 2.7% for urine creatinine (3.9 to 7.1 mmoJJL). The within-
assay variability ranged from 2% to 12.5% for (3-core and
from 1.1% to 1.5% for creatunine.
The concentration of /3-core was expressed as either pg/L,
mg/mol of creatinine, or &g/h. The CVs for the three indices
were compared by using one-way analysis of variance.
Variations with time (CVs) in individual women ranged
from 14.9% to 103% (mean 45.2%) for /3-core concentration,
from 7.4% to 43.6% (mean 19.1%) for /3-core per mole of
creatinine, and from 9.6% to 42.6% (mean 2 1.9%) for (3-core
per unit of time. The CV for concentration Q.tg’L) was
significantly greater than the CVs for (3-core expressed per
unit of creatinine or time (P <0.01). There was no evidence
for any systematic early-morning peak or time-related pat-
tern in any of the three indices, although six subjects had
their highest /3-core concentration (zgJL) in the early-
morning specimen. Four women had no measurable /3-core
in the whole 24-h collection. Urine (3-core and creatinine
concentrations were closely related; for all patients, the
coefficient of linear correlation (r) ranged from 0.732 to
0.997. In five cancer patients, from whom at least six mea-
surements of urinary (3-core exceeded the RIA detection
limit, we found a modest to strong correlation with creati-
nine content (r = 0.666 to 0.985) and a significant fit to a
linear regression model (P = 0.07 to <0.0001). However,
when all data were combined, the correlation decreased (r
= 0.402) because of the variable output of /3-core from each
individual patient. Hourly /3-core excretion and (3-core per
unit creatinine in early-morning samples were also related
(r = 0.756).
The advantages of reporting concentrations of substances
excreted in urine after adjustment for urine concentration
has been shown for several different solutes (8-11). Other
urine tumor markers, e.g., tumor-associated antigen, show
a systematic diurnal excretion pattern (13). In this study
we were not able to identify a systematic diurnal rhythm in
urine /3-core production in women with gynecological neo-
plasia, similar to observations made during the first tri-
mester of pregnancy (14).
Paterson (15) noted that creatinine output is not suffi-
ciently constant to act as a reference against which the
excretion of other solutes can be standardized, and sug-
gested that the time-related excretion rate of a solute
should be more reliable than this. By contrast, the present
data show that time-to-time variation is equally reduced by
expressing results per unit of creatinine or per unit of time.
However, we recognize that adjustment for urinary creat-
mine within an individual does not allow for systematic
differences in creatimne excretion between individuals,
e.g., because of differences in lean body mass.
The clinical importance of the present findings is that
measurement of (3-core in a single early-morning or ran-
dom urine specimen is likely to give a more accurate result
when the value is related to creatunine concentration.
Whether this index will better distinguish between the
benign and malignant group and whether creatunine-cor-
rected /3-core is a better prognostic indicator are the sub-
jects of on-going studies.
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Genetic changes such as point mutations, rearrange-
ments, and amplification or deletion in a single cell may
result in malignant transformation. It is widely accepted
that mutations in the p53 tumor suppressor gene are
among the most frequent alterations that occur during the
malignant progression of many tumor types (1, 2). The
product of p53 is a 393-amino acid nuclear phosphoprotein
that was first described in 1979. Most mutations in p53
occur in exons 5 through 8 in four evolutionarily conserved
domains (1). Mutations have been shown to cluster to these
conserved regions of p53 in many human tumors, including
breast, colon, lung, brain, and leukemia/lymphoma.
Li-Fraumeni syndrome (LFS) is a rare condition in which
affected family members develop many different types of
tumors similar to those sporadic tumor types that contain
p53 mutations (3). Germlinep53 mutations were first de-
scribed in LFS patients who developed breast carcinomas,
sarcomas, and brain tumors.
We examined the ability of a heteroduplex technique to
detect single-base mutations in cells from two previously
characterized LFS patients.
Two human fibroblast cell lines, MDAHO41 and
MDAHO87, derived from two LFS patients were obtained
from Michael Taunsky (University of Texas-MD Anderson
Cancer Center, Houston, TX) (4). MDAHO41 contained a
single-base deletion at codon 184 (exon 5), and MDAHO87,
a point mutation at codon 248 (exon 7). The cells were
grown as previously described (5).
We resuspended a cell pellet containing 1 x 10-2 x iO
fibroblasts in 200 L of extraction buffer (50 mmol/L Tris-
HC1, pH 7.6; 100 mmol/L NaCI; 1 mmol/L EDTA 5 g/L
sodium dodecyl sulfate) and digested it overnight with 290
mg/L proteinase K at 37#{176}C.The samples were then incu-
bated for 10 mm at 65#{176}Cto inactivate the proteinase before
being exposed to RNAse A for 1 h at 37#{176}C.DNA was
ethanol-precipitated after the addition of saturated NaC1
and resuspended in 10 mmol/L Tris-1 mmol/L EDTA, pH
7.6.
We incubated genomic DNA (0.5-1.0 jig), isolated as
described above, in a total reaction volume of 100 jiL con-
taining 300 ng of both the forward and reverse exon-specific
primers, 2.5 U of Taq polymerase, 200 nmo]/L each deoxy-
nucleotide triphosphate, 1.0 mmol/L MgC12, 67 mmol/L
Tris-HC1 (pH 8.8), 10 mmol/L 2-mercaptoethanol, 16.6
mmol/L ammonium sulfate, and 6.7 jimol/L EDTA. The
primers used were as follows: exon 5, 5’G11CACTI’GTGC-
CCTGACTF3’ and 5’AGGAATCAGAGGCCTGGGGA3’;
exon 7, 5’TGCVFGCCACAGGTCTCC3’ and 5’AACCAC-
CCrFGTCCTTFCTG3’. DNA was initially denatured at
94#{176}Cfor 6 min before amplification. Polymerase chain re-
action (PCR) amplification was accomplished with 35 cycles
consisting of 2 miii annealing at 55#{176}C,3 mm extension at
72#{176}C,and 1 mm denaturation at 94#{176}C.The final cycle
included a 2-mm annealing step at 55#{176}Cand a 10-mm
extension step at 72#{176}C.
The PCR-amplifled product from each patient was heat-
denatured at 100#{176}Cin a beaker of water for 3 mm and then
slowly cooled to 45#{176}Cby allowing the sample to remain in
the water at room temperature on the benchtop. We mixed
an aliquot of 40 jiL of this product with 6 jiL of gel loading
buffer and electrophoresed the product on a 38-cm vertical
Hydrolink-MDE gel (AT Biochem, Malvern, PA) that was
1.5 mm thick. We diluted the MDE gel to aix concentra-
tion (from 2x stock) in 0.6x Tris-boric aeid-EDTA (TBE)
buffer (lx = 133 mmol/L Tris, 81 mmol/L boric acid, and 3
mmol/L EDTA) and 150 g/L urea. After gel polymerization,
electrophoresis was carried out for 16 h at 500 V. The gel
